Ulcerative colitis (subacute manifestations) - infliximab: costing statement

A costing statement has been produced by NICE to provide an implementation tool to estimate the financial impact to the NHS of implementing the technology appraisal TA140 Colitis (ulcerative) -infliximab.

The Institute would welcome feedback from users to inform the development of future templates. Please email your comments to costing@nice.org.uk